{"title":"IgG1和IgG4在过敏原免疫治疗中作为优势ige阻断抗体的作用","authors":"Barbara Bohle","doi":"10.1007/s15007-024-6398-7","DOIUrl":null,"url":null,"abstract":"<p>Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E(IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e. g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.</p><p><b>Cite this as</b> Bohle B. The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy. Allergo J Int 2024;33: 282-8</p><p><b>https://doi.org/10.1007/s40629-024-00309-5</b></p>","PeriodicalId":7418,"journal":{"name":"Allergo Journal","volume":"33 8","pages":"26 - 33"},"PeriodicalIF":1.1000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy\",\"authors\":\"Barbara Bohle\",\"doi\":\"10.1007/s15007-024-6398-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E(IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e. g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.</p><p><b>Cite this as</b> Bohle B. The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy. Allergo J Int 2024;33: 282-8</p><p><b>https://doi.org/10.1007/s40629-024-00309-5</b></p>\",\"PeriodicalId\":7418,\"journal\":{\"name\":\"Allergo Journal\",\"volume\":\"33 8\",\"pages\":\"26 - 33\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s15007-024-6398-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s15007-024-6398-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy
Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E(IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e. g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.
Cite this as Bohle B. The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy. Allergo J Int 2024;33: 282-8
期刊介绍：
The Allergo Journal publishes original articles, reviews and case reports, guidelines and position papers in German and English. The topics concern allergological and immunological clinical pictures, current developments in diagnosis and therapy, research work concerning antigens and allergens and aspects related to occupational and environmental medicine. The quality of the contributions is guaranteed by an international board of editors; all contributions will be reviewed by at least two independent peers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
